GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Agilent Technologies Inc (NYSE:A) » Definitions » EBIT

A (Agilent Technologies) EBIT : $1,587 Mil (TTM As of Jan. 2025)


View and export this data going back to 1999. Start your Free Trial

What is Agilent Technologies EBIT?

Agilent Technologies's earnings before interest and taxes (EBIT) for the three months ended in Jan. 2025 was $395 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jan. 2025 was $1,587 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Agilent Technologies's annualized ROC % for the quarter that ended in Jan. 2025 was 13.69%. Agilent Technologies's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jan. 2025 was 64.32%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Agilent Technologies's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jan. 2025 was 4.40%.


Agilent Technologies EBIT Historical Data

The historical data trend for Agilent Technologies's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Agilent Technologies EBIT Chart

Agilent Technologies Annual Data
Trend Oct15 Oct16 Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23 Oct24
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 920.00 1,441.00 1,588.00 1,434.00 1,617.00

Agilent Technologies Quarterly Data
Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 425.00 394.00 365.00 433.00 395.00

Competitive Comparison of Agilent Technologies's EBIT

For the Diagnostics & Research subindustry, Agilent Technologies's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Agilent Technologies's EV-to-EBIT Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Agilent Technologies's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Agilent Technologies's EV-to-EBIT falls into.



Agilent Technologies EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jan. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,587 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Agilent Technologies  (NYSE:A) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Agilent Technologies's annualized ROC % for the quarter that ended in Jan. 2025 is calculated as:

ROC % (Q: Jan. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Oct. 2024 ) + Invested Capital (Q: Jan. 2025 ))/ count )
=1504 * ( 1 - 13.35% )/( (9579 + 9464)/ 2 )
=1303.216/9521.5
=13.69 %

where

Note: The Operating Income data used here is four times the quarterly (Jan. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Agilent Technologies's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jan. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Jan. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Oct. 2024  Q: Jan. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=1580/( ( (1778 + max(780, 0)) + (1816 + max(539, 0)) )/ 2 )
=1580/( ( 2558 + 2355 )/ 2 )
=1580/2456.5
=64.32 %

where Working Capital is:

Working Capital(Q: Oct. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1324 + 972 + 334) - (938 + 544 + 368)
=780

Working Capital(Q: Jan. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1080 + 997 + 315) - (983 + 612 + 258)
=539

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Jan. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Agilent Technologies's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Jan. 2025 )
=1587/36065.561
=4.40 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Agilent Technologies EBIT Related Terms

Thank you for viewing the detailed overview of Agilent Technologies's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Agilent Technologies Business Description

Traded in Other Exchanges
Address
5301 Stevens Creek Boulevard, Santa Clara, CA, USA, 95051
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life science and diagnostic firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools, cross lab consisting of consumables and services related to life science and applied tools, and diagnostics and genomics. Over half of its sales are generated from the biopharmaceutical, chemical, and advanced materials end markets, which we view as the stickiest end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the US and China representing the largest country concentrations.
Executives
Padraig Mcdonnell officer: Senior Vice President 5301 STEVENS CREEK BLVD, SANTA CLARA CA 95051
Dominique Grau officer: Senior Vice President 5301 STEVENS CREEK BLVD., SANTA CLARA CA 95051
Philip Binns officer: Senior Vice President 5301 STEVENS CREEK BLVD., SANTA CLARA CA 95051
Michael R. Mcmullen officer: CEO and President 5301 STEVENS CREEK BLVD., MS 1A-LC, SANTA CLARA CA 95051
Rodney Gonsalves officer: V.P., Corporate Controller 5301 STEVENS CREEK BLVD., SANTA CLARA CA 95051
Heidi Fields director 5301 STEVENS CREEK BLVD, MS 1A-LC, SANTA CLARA CA 95051
Henrik Ancher-jensen officer: Sr. Vice President 5301 STEVENS CREEK BLVD., SANTA CLARA CA 95051
George A Scangos director C/O EXELIXIS INC, 170 HARBOR WAY, SAN FRANCISCO CA 94083
Otis W Brawley director 5203 BRISTOL INDUSTRIAL WAY, BUFORD GA 30518
Mikael Dolsten director 5 GIRALDA FARMS, MADISON NJ 07940
Mala Anand director C/O COTIVITI HOLDINGS, INC., 115 PERIMETER CENTER PLACE, SUITE 700, ATLANTA GA 30346
Sue H. Rataj director C/O CABOT CORPORATION, TWO SEAPORT LANE, SUITE 1300, BOSTON MA 02210
Dow R Wilson director VARIAN MEDICAL SYSTEMS INC, 3100 HANSEN WAY MAIL STOP E327, PALO ALTO CA 94304
Boon Hwee Koh director C/O AGILENT TECHNOLOGIES, 5301 STEVENS CREEK BLVD, MS 1A-LC, SANTA CLARA CA 95051
Hans Edgar Bishop director 60 WEST 66TH STREET, 26A, NEW YORK NY 10023